Full text
Earnings transcript
Read the complete earnings call transcript.
MDT
Medtronic plc
$86.63
0.57
(0.66%)
| Exchange: | NYSE |
| Market Cap: | 111.223B |
| Shares Outstanding: | 890M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Devices | |||||
| CEO: | Geoffrey Straub Martha | |||||
| Full Time Employees: | 95000 | |||||
| Address: |
| |||||
| Website: | https://www.medtronic.com |
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company’s Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company’s Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 31,227,000 | 32,364,000 | 33,537,000 |
| Gross Profit | 20,508,000 | 21,148,000 | 21,905,000 |
| EBITDA | 8,697,000 | 8,203,000 | 9,218,000 |
| Operating Income | 5,485,000 | 5,144,000 | 5,955,000 |
| Net Income | 3,758,000 | 3,676,000 | 4,662,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 90,948,000 | 89,981,000 | 91,680,000 |
| Total Liabilities | 39,283,000 | 39,561,000 | 43,424,000 |
| Total Stockholders Equity | 51,483,000 | 50,214,000 | 48,024,000 |
| Total Debt | 24,364,000 | 25,024,000 | 28,516,000 |
| Cash and Cash Equivalents | 1,543,000 | 1,284,000 | 2,218,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 6,039,000 | 6,787,000 | 7,044,000 |
| Capital Expenditure | -1,459,000 | -1,587,000 | -1,859,000 |
| Free Cash Flow | 4,580,000 | 5,200,000 | 5,185,000 |
| Net Income | 3,784,000 | 3,676,000 | 4,691,000 |
| Net Change in Cash | -2,171,000 | -259,000 | 934,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 43,071,565.762 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 45,224,788.785 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 44,476,250 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 12,396,180.490 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 13,015,887.268 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 12,800,454.610 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 9,570,825.825 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 10,198,968.428 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 9,980,601.257 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 14,218,012.681 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 14,928,796.042 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 14,681,701.845 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 7.740 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 7.910 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 7.420 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 11 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 3 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates MDT intrinsic value between $57.52 – $89.80 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about MDT valuation
Is MDT (MDT) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for MDT (MDT) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is MDT a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether MDT trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is MDT’s P/E ratio?
You can see MDT’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for MDT?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is MDT a good long-term investment?
Whether MDT fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
MDT
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0.66
Chart data temporarily unavailable.
Daily snapshotTrading Metrics:
| Open: | — | Previous Close: | — | |
| Day Low: | — | Day High: | — | |
| Year Low: | Year High: | |||
| Price Avg 50: | Price Avg 200: | |||
| Volume: | Average Volume: | |||
| Session data unavailable | ||||
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
Relevant news
